Global RNA Therapeutics Markets 2021-2027

DublinAnd the June 21 2022 /PRNewswire/ – file “Global RNA Therapeutics Growth Opportunities” Report added to Show.



This research service provides an overview of the global DNA Therapeutics industry from 2021 to 2027, including emerging trends, growth drivers, and growth opportunities.

Scientific advances in nucleic acid-based therapies have greatly influenced the global biopharmaceutical industry. The RNA therapy market is expected to witness significant clinical advances as therapies target ‘untreatable’ pathways.

Technically advanced platforms have been integrated into bioprocessing of RNA therapeutics to overcome stability issues. Technological advantages, along with the growing need to build clinically superior portfolios in RNA therapeutics for a competitive advantage, are expected to drive strategic partnerships among stakeholders in the RNA therapeutics industry.

Motivated by the COVID-19 pandemic, biopharmaceutical companies are likely to prioritize microRNA, small interfering RNA, and antisense oligonucleotides as promising therapeutic avenues during the forecast period. Medium and large companies have ramped up production of raw materials and final formulation of RNA therapies, which is likely to prompt stakeholders to seek synergistic partnerships.

In the industry’s shift to personalized therapies, RNA developers are taking advantage of the high-resolution RNA to treat untapped areas of chronic disease such as cystic fibrosis, solid tumors, and spinal muscular atrophy. They participate in co-development programs to improve the stability profile of RNA therapies by improving drug delivery vectors, such as lipid nanoparticles.

Expand production of starting materials, including plasmid DNA, oligonucleotides, and delivery materials, to ensure continued manufacturing is expected to reduce the operational time frame for production of RNA therapeutics. Technology transfer and outsourcing of critical processes to contract development and manufacturing organizations (CDMOs) stimulate the development of cost-effective and efficient models of RNA therapies.

The search service highlights the following:

  • RNA Therapeutics Market Size, Including Key Segments From 2022 to 2027

  • Developments in bioprocessing and the methods and technologies shaping the market

  • Current and future research and development, investment forecasts, and trends

Main topics covered:

1. Strategic imperatives

  • Why is it getting harder to grow?

  • Strategic imperative

  • The impact of the 3 most important strategic imperatives on the RNA therapies industry

  • Growth opportunities fuel the growth pipeline

2. Analysis of growth opportunities

  • Analysis scope

  • fragmentation

  • Research Methodology

  • main socket

  • growth metrics

  • growth engines

  • growth restrictions

  • Main directions

  • The main indicators of the disease

  • Pipeline shot of 2021

  • Value Chain – Key Stakeholders

  • Principal stakeholders driving the turmoil

  • Regional snapshot of manufacturers

  • Strategies to meet manufacturing and supply needs

  • The evolution of the role of stakeholders in the supply chain

  • Global changes in the biosynthesis of RNA therapies

  • Distribution and Supply Framework

  • Key Partnership Topics

  • Notable Partnerships

  • Notable mRNA manufacturing partnerships by region – Europe

  • Notable mRNA manufacturing partnerships by region – United States

  • prediction assumptions

  • Income forecast

  • Revenue forecast analysis

  • Percentage of revenue forecast by product type

  • Main modalities under development

  • competitive environment

  • Market share analysis

3. The universe’s growth opportunities

  • Growth Opportunity 1 – Increased focus on immuno-oncology to meet demand for targeted tumour-specific therapies

  • Opportunity Growth 2 – Optimizing LNP Delivery to Address Stability Issues of RNA Therapeutics

  • Growth Opportunity 3 – Expanding CDMO Capabilities to Support Biopharmaceutical Companies

For more information about this report visit

Media contact:

Research and Markets
Laura Wooddirector, mentor

For EST office hours, call +1-917-300-0470
For the US/Canada, call toll free +1-800-526-8630
For GMT office hours, call +353-1-416-8900

US Fax: 607-646-1907
Fax (outside the US): +353-1-481-1716



View original content:—increase-focus-on-immuno-oncology-to-meet-the-demand-for-tumor- Specific treatments – 301571942.html

SOURCE Research & Markets